Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Autor: van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Kern W; MLL Munich Leukemia Laboratory, Munich, Germany., Porwit A; Department of Clinical Sciences, Division of Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden., Valent P; Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Kordasti S; Comprehensive Cancer Centre, King's College London, London, UK., Cremers E; Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands., Alhan C; Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Duetz C; Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Dunlop A; Department of Haemato-Oncology, Royal Marsden Hospital, London, UK., Hobo W; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Preijers F; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Wagner-Ballon O; Department of Hematology and Immunology, Assistance Publique-Hôpitaux de Paris, University Hospital Henri Mondor, Créteil, France.; Université Paris-Est Créteil, Inserm U955, Créteil, France., Chapuis N; Laboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Centre-Université de Paris, Paris, France.; Institut Cochin, Université de Paris, INSERM U1016, CNRS UMR 8104, Paris, France., Fontenay M; Laboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Centre-Université de Paris, Paris, France.; Institut Cochin, Université de Paris, INSERM U1016, CNRS UMR 8104, Paris, France., Bettelheim P; Department of Hematology, Ordensklinikum Linz, Elisabethinen, Linz, Austria., Eidenschink-Brodersen L; HematoLogics, Inc., Seattle, Washington, USA., Font P; Department of Hematology, Hospital General Universitario Gregorio Marañon - IiSGM, Madrid, Spain., Johansson U; Laboratory Medicine, SI-HMDS, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Loken MR; HematoLogics, Inc., Seattle, Washington, USA., Te Marvelde JG; Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Matarraz S; Cancer Research Center (CIC/IBMCC-USAL/CSIC), Department of Medicine and Cytometry Service, University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL) and CIBERONC, Salamanca, Spain., Ogata K; Metropolitan Research and Treatment Centre for Blood Disorders (MRTC Japan), Tokyo, Japan., Oelschlaegel U; Department of Internal Medicine, University Hospital Carl-Gustav-Carus TU Dresden, Dresden, Germany., Orfao A; Cancer Research Center (CIC/IBMCC-USAL/CSIC), Department of Medicine and Cytometry Service, University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL) and CIBERONC, Salamanca, Spain., Psarra K; Department of Immunology - Histocompatibility, Evangelismos Hospital, Athens, Greece., Subirá D; Department of Hematology, Flow Cytometry Unit, Hospital Universitario de Guadalajara, Guadalajara, Spain., Wells DA; HematoLogics, Inc., Seattle, Washington, USA., Béné MC; Hematology Biology, Nantes University Hospital and CRCINA, Nantes, France., Della Porta MG; IRCCS Humanitas Research Hospital, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Burbury K; Department of Haematology, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Australia., Bellos F; MLL Munich Leukemia Laboratory, Munich, Germany., van der Velden VHJ; Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Westers TM; Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Saft L; Department of Clinical Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Stockholm, Sweden., Ireland R; Department of Haematology and SE-HMDS, King's College Hospital NHS Foundation Trust, London, UK.
Jazyk: angličtina
Zdroj: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2023 Jan; Vol. 104 (1), pp. 77-86. Date of Electronic Publication: 2021 Dec 13.
DOI: 10.1002/cyto.b.22044
Abstrakt: This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.
(© 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.)
Databáze: MEDLINE
Externí odkaz: